Eli Lilly and Company $LLY Stock Holdings Increased by Sax Wealth Advisors LLC

Key Points

• Sax Wealth Advisors increased its Eli Lilly stake by 450% in the third quarter, bringing its holdings to 8,410 shares valued at approximately $9.7 million. Institutional investors collectively own 82.53% of the company.
• Wall Street remains broadly bullish: 25 analysts rate the stock a Buy, with a consensus “Moderate Buy” rating and average price target of $1,313.43.
• Eli Lilly’s growth outlook is supported by strong diabetes and obesity-drug demand, its retatrutide pipeline, and rising revenue expectations, though high valuation, insider selling, and concerns about retatrutide’s tolerability pose risks.

Sax Wealth Advisors LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 450.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,410 shares of the company's stock after buying an additional 6,881 shares during the period. Sax Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $9,731,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Coastal Bridge Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $2,959,000. Mosaic Family Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 70.6% during the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock worth $4,144,000 after buying an additional 1,430 shares during the last quarter. Moran Wealth Management LLC boosted its position in Eli Lilly and Company by 85.6% during the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company's stock valued at $25,072,000 after purchasing an additional 9,638 shares during the last quarter. Generali Investments Management Co LLC raised its stake in shares of Eli Lilly and Company by 17.5% during the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company's stock worth $12,258,000 after purchasing an additional 1,521 shares in the last quarter. Finally, Amundi grew its stake in shares of Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company's stock valued at $4,649,464,000 after buying an additional 454,549 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on LLY shares. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a research note on Friday, August 7th. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a research note on Friday, August 7th. BMO Capital Markets reissued an "outperform" rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. Bank of America increased their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research note on Friday, July 10th. Finally, Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,313.43.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong obesity-drug pipeline remains the key catalyst. Investors are focusing less on Eli Lilly’s October 29 earnings report and more on retatrutide, an investigational next-generation obesity treatment that could become a larger growth driver than Zepbound if late-stage results confirm its potential. Retatrutide and earnings article
• Positive Sentiment: Revenue and earnings expectations are rising. Analysts at Erste Group modestly increased their FY2026 EPS forecast to $36.55 and FY2027 estimate to $47.30. Separately, RBC said strong diabetes and weight-loss sales could lead Lilly to raise its full-year revenue outlook, which is projected to reach as much as $87 billion. Lilly revenue outlook article
• Positive Sentiment: Analyst support remains favorable. Royal Bank of Canada reaffirmed its “Outperform” rating and established a $1,500 price target. Lilly also received an A+ profitability grade among mega-cap healthcare companies. RBC rating article
• Positive Sentiment: Additional pipeline and partnership developments support long-term growth. Prelude Therapeutics is collaborating with Lilly to evaluate its cancer drug candidate PRT13722 alongside Lilly therapies Verzenio and Inluriyo in breast cancer patients. New Phase 3b data also indicated that combining Taltz and Zepbound improved psoriasis outcomes and reduced weight in studied patients. Prelude collaboration article
• Neutral Sentiment: A potential stock split is speculative. Lilly’s share price could support a split, but management has not announced one, and such an action would not change the company’s underlying value. Stock split article
• Negative Sentiment: Retatrutide’s clinical profile still carries risk. A drug combination generated more weight loss than Zepbound alone, but discontinuation rates were substantially higher, raising questions about tolerability and commercial adoption. Lilly is also contending with illicit online sales of retatrutide before launch. Weight-loss combination article
• Negative Sentiment: Profit-taking and valuation pressure may be weighing on the stock. After a major multiyear rally, investors may be locking in gains ahead of earnings, leaving Lilly vulnerable if results or guidance fail to exceed already-high expectations.

Insider Transactions at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company's stock, valued at $14,131,250. This represents a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $11.77 during midday trading on Tuesday, reaching $1,170.85. 605,069 shares of the company were exchanged, compared to its average volume of 2,945,758. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65. The stock's 50-day moving average price is $1,175.57 and its 200-day moving average price is $1,100.31. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a market cap of $1.10 trillion, a P/E ratio of 39.34, a PEG ratio of 1.47 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm's quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 36.19 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.